Differential cholinergic systems' changes in progressive supranuclear palsy versus Parkinson's disease: an
Prabesh Kanel1,2,3, C Chauncey Spears4, Stiven Roytman5
1Department of Radiology, University of Michigan, MI, Ann Arbor, USA. prabeshk@umich.edu.
Journal of Neural Transmission (Vienna, Austria : 1996)
|October 12, 2022
Summary
Progressive Supranuclear Palsy (PSP) shows more widespread brain cholinergic deficits than Parkinson's disease (PD). This study used PET imaging to map these differences, revealing specific vulnerabilities in PSP patients.
Area of Science:
- Neuroscience
- Neurology
- Radiology
Background:
- Cholinergic system deficits are implicated in neurodegenerative diseases.
- Previous research suggests more severe brainstem cholinergic loss in Progressive Supranuclear Palsy (PSP) compared to Parkinson's disease (PD).
- The precise distribution of these subcortical deficits in PSP remains unclear.
Purpose of the Study:
- To investigate and compare changes in the cholinergic system between PSP, PD, and healthy controls.
- To identify disease-specific patterns of cholinergic deficits using advanced neuroimaging.
Main Methods:
- Employed [18F]-fluoroethoxybenzovesamicol (FEOBV) positron emission tomography (PET) to assess vesicular acetylcholine transporter binding.
- Utilized whole-brain voxel-based analysis with Statistical Parametric Mapping (SPM12) for inter-group comparisons.
- Compared 8 PSP patients, 107 PD patients, and 19 older controls.
Main Results:
- PSP patients exhibited significantly lower FEOBV binding in multiple brain regions compared to PD patients, including the tectum, metathalamus, epithalamus, pulvinar, frontal opercula, insulae, temporal pole, anterior cingulum, brainstem, and cerebellum.
- More extensive and diffuse cholinergic reductions were observed in PSP patients compared to controls.
- PSP showed a higher frequency of midbrain cholinergic loss than PD.
Conclusions:
- Findings indicate distinct cholinergic vulnerability patterns in PSP, particularly in the tectum and striatal cholinergic interneurons.
- Suggests specific involvement of projections from the pedunculopontine nucleus and medial vestibular nucleus in PSP.
- Highlights the utility of FEOBV-PET for differentiating neurodegenerative conditions based on cholinergic system integrity.
Related Concept Videos
01:15Parkinson's Disease: Overview
671
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
671
01:24Parkinson's Disease: Treatment
353
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
353
01:37Neural Regulation
39.7K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.7K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
751
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
751
01:28Cholinergic Antagonists: Pharmacological Actions
1.2K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.2K
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.3K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.3K